NSAIDs and spinal manipulation did nothing to speed recovery. Most episodes of acute lower back pain will resolve spontaneously, and guideline-recommended treatment consists primarily of ...
A study by researchers at The George Institute for International Health in Australia found that it is rare for patients presenting to PCPs with acute lower back pain to have previously undiagnosed ...
According to the Global Burden of Disease Study, low back pain affects nearly 80% of people at some point in their lives.
The greenlight for Journavx (suzetrigine), which comes on the heels of a $7.4 billion opioid settlement, could spark momentum ...
Despite high demand for an option like Journavx, doctors fear the drug’s price could be a hangup for insurers and limit ...
A study reveals brain biomarkers PAF and CME can predict pain sensitivity and chronic pain risk with 88% accuracy. The findings could enable personalized treatment and prevent transitions from acute ...
The encouraging result comes just days after the US FDA approved Vertex Pharma's non-opioid painkiller Journavx (suzetrigine) ...
GlobalData on MSN13d
FDA approves Vertex’s acute pain treatment JournavxThe FDA has approved Vertex Pharmaceuticals’ oral Journavx (suzetrigine) to treat adults with moderate-to-severe acute pain.
Vertex's Journavx got FDA approval for acute pain but faces adoption challenges. Click here to read more about VRTX stock and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback